Med (New York, N.Y.) - JoVE Visualize

Showing results (171-180 of 861) with videos related to

Pageof 87

Sort By:

Med (New York, N.Y.)|June 15, 2026

Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)Yaqi Yin, Jianhua Ma, Dexue Liu, et al.

Med (New York, N.Y.)|August 13, 2022

IV tenecteplase: A non-inferior alternative to alteplase?Adeel S Zubair, Kevin N Sheth

Med (New York, N.Y.)|December 22, 2022

Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospectsPengfei Zhang, Yufen Xiao, Xue Sun, et al.

Med (New York, N.Y.)|July 10, 2026

Q&A with Carolyn S.P. LamCarolyn S P Lam

Med (New York, N.Y.)|May 29, 2026

First human decedent model of orthotopic multi-organ xenotransplantation: Whole liver and bilateral kidneys from a six-gene-edited pigJixiang Liao, Sanqi An, Jianhui Dong, et al.

Med (New York, N.Y.)|June 5, 2026

Inhibiting glycan degradation prevents HIV-induced inflammaging and cognitive impairmentLeila B Giron, Alejandra Borjabad, Eran Hadas, et al.

Med (New York, N.Y.)|June 12, 2026

Entering a new age of innovation in IBD clinical trial designJoana Roseira, Irene Marafini, Gülden Bilican, et al.

Med (New York, N.Y.)|May 9, 2026

Long-acting injectable ART: Promise for adherence, but persistent gaps in global accessLauren Jennings, Linda-Gail Bekker

Med (New York, N.Y.)|June 12, 2026

National- and state-level burdens of substance use disorders in the USA, 1990-2023, with forecasts up to 2050: Global Burden of Disease Study 2023,

Med (New York, N.Y.)|July 21, 2026

Immune-stromal interactions at the crossroads of tissue injury, repair, and tumor progressionDerek Ning, Daniel Naveed Tavakol, Pamela L Graney, et al.

Pageof 87

Showing results (171-180 of 861) with videos related to

Sort By:

Pageof 87

Med (New York, N.Y.)|June 15, 2026

Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)Yaqi Yin, Jianhua Ma, Dexue Liu, et al.

Med (New York, N.Y.)|August 13, 2022

IV tenecteplase: A non-inferior alternative to alteplase?Adeel S Zubair, Kevin N Sheth

Med (New York, N.Y.)|December 22, 2022

Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospectsPengfei Zhang, Yufen Xiao, Xue Sun, et al.

Med (New York, N.Y.)|July 10, 2026

Q&A with Carolyn S.P. LamCarolyn S P Lam

Med (New York, N.Y.)|May 29, 2026

First human decedent model of orthotopic multi-organ xenotransplantation: Whole liver and bilateral kidneys from a six-gene-edited pigJixiang Liao, Sanqi An, Jianhui Dong, et al.

Med (New York, N.Y.)|June 5, 2026

Inhibiting glycan degradation prevents HIV-induced inflammaging and cognitive impairmentLeila B Giron, Alejandra Borjabad, Eran Hadas, et al.

Med (New York, N.Y.)|June 12, 2026

Entering a new age of innovation in IBD clinical trial designJoana Roseira, Irene Marafini, Gülden Bilican, et al.

Med (New York, N.Y.)|May 9, 2026

Long-acting injectable ART: Promise for adherence, but persistent gaps in global accessLauren Jennings, Linda-Gail Bekker

Med (New York, N.Y.)|June 12, 2026

National- and state-level burdens of substance use disorders in the USA, 1990-2023, with forecasts up to 2050: Global Burden of Disease Study 2023,

Med (New York, N.Y.)|July 21, 2026

Immune-stromal interactions at the crossroads of tissue injury, repair, and tumor progressionDerek Ning, Daniel Naveed Tavakol, Pamela L Graney, et al.

Pageof 87